GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Reunion Neuroscience Inc (TSX:REUN) » Definitions » EV-to-FCF

Reunion Neuroscience (TSX:REUN) EV-to-FCF : 0.26 (As of May. 16, 2024)


View and export this data going back to 2020. Start your Free Trial

What is Reunion Neuroscience EV-to-FCF?

EV-to-FCF is calculated as enterprise value divided by its free cash flow. As of today, Reunion Neuroscience's Enterprise Value is C$-7.19 Mil. Reunion Neuroscience's Free Cash Flow for the trailing twelve months (TTM) ended in Mar. 2023 was C$-28.16 Mil. Therefore, Reunion Neuroscience's EV-to-FCF for today is 0.26.

The historical rank and industry rank for Reunion Neuroscience's EV-to-FCF or its related term are showing as below:

TSX:REUN's EV-to-FCF is not ranked *
in the Biotechnology industry.
Industry Median: 7.56
* Ranked among companies with meaningful EV-to-FCF only.

EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.

As of today (2024-05-16), Reunion Neuroscience's stock price is C$1.42. Reunion Neuroscience's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Mar. 2023 was C$-4.160. Therefore, Reunion Neuroscience's PE Ratio for today is At Loss.


Reunion Neuroscience EV-to-FCF Historical Data

The historical data trend for Reunion Neuroscience's EV-to-FCF can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Reunion Neuroscience EV-to-FCF Chart

Reunion Neuroscience Annual Data
Trend Mar20 Mar21 Mar22 Mar23
EV-to-FCF
- -11.78 -1.28 0.46

Reunion Neuroscience Quarterly Data
Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23
EV-to-FCF Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -1.28 -0.26 0.28 0.37 0.46

Competitive Comparison of Reunion Neuroscience's EV-to-FCF

For the Biotechnology subindustry, Reunion Neuroscience's EV-to-FCF, along with its competitors' market caps and EV-to-FCF data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Reunion Neuroscience's EV-to-FCF Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Reunion Neuroscience's EV-to-FCF distribution charts can be found below:

* The bar in red indicates where Reunion Neuroscience's EV-to-FCF falls into.



Reunion Neuroscience EV-to-FCF Calculation

Reunion Neuroscience's EV-to-FCF for today is calculated as:

EV-to-FCF=Enterprise Value (Today)/Free Cash Flow (TTM)
=-7.193/-28.163
=0.26

Reunion Neuroscience's current Enterprise Value is C$-7.19 Mil.
Reunion Neuroscience's Free Cash Flow for the trailing twelve months (TTM) ended in Mar. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was C$-28.16 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Reunion Neuroscience  (TSX:REUN) EV-to-FCF Explanation

EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.

Reunion Neuroscience's PE Ratio for today is calculated as:

PE Ratio=Share Price (Today)/Earnings per Share (Diluted) (TTM)
=1.42/-4.160
=At Loss

Reunion Neuroscience's share price for today is C$1.42.
Reunion Neuroscience's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Mar. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was C$-4.160.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Enterprise Value is used because it is a more complete measure in reflecting how much an investor pays when buying a company. Free Cash Flow is an important financial metric because it represents the actual amount of cash at a company's disposal. Companies with a low EV-to-FCF ratio, combined with a strong balance sheet are generally considered as undervalued.


Reunion Neuroscience EV-to-FCF Related Terms

Thank you for viewing the detailed overview of Reunion Neuroscience's EV-to-FCF provided by GuruFocus.com. Please click on the following links to see related term pages.


Reunion Neuroscience (TSX:REUN) Business Description

Traded in Other Exchanges
N/A
Address
30 Duncan Street, Lower North Suite, Toronto, ON, CAN, M5V 2C3
Reunion Neuroscience Inc is engaged in novel psychedelic drug development, committed to innovating therapeutic solutions for mental health conditions by developing proprietary serotonin receptor agonist compounds. The company's asset, RE-104 (previously known as FT-104), is a proprietary, novel psychedelic drug being developed for post-partum and treatment-resistant depression as a potential fast-acting antidepressant with durable efficacy.